Grand Pharma Announces 2022 Interim Results, Continue to Deepen Technological Innovation, Profitability Improved Steadily 2022-8-11 Corporate News READ MORE
Grand Pharma Acquired 100% Equity of Hubei Bafeng, Further Expanding the Strategic Plan on High-quality Amino Acid Industry 2022-8-7 Corporate News READ MORE
The IND of Grand Pharma’s Global Innovative RDC TLX591-CDx and TLX250-CDx has been accepted by NMPA 2022-8-1 Corporate News READ MORE
Grand Pharma’s Global Innovative Product STC3141 Made Significant Progress in Clinical Trials in China and Europe 2022-7-27 Corporate News READ MORE
Grand Pharma Enters into Strategic Cooperation with XELTIS, Introduced A Global Innovative Endogenous Tissue Repair Product 2022-7-18 Corporate News READ MORE
Grand Pharma Reaches Strategic Cooperation with Eye Hospital, WMU, Strategically Planning the New Ophthalmic Preparation, And Building Public Eye Protection Ecosystem 2022-5-25 Corporate News READ MORE
Grand Pharma’s Global Innovative Product STC3141 Approved for Phase Ib Clinical Study in Belgium, Another Milestone of Global Innovative Products and Continues the Globalization Development Process 2022-4-26 Corporate News READ MORE
The Phase III Clinical Trial in China of Grand Pharma’s Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment, Milestone Progress in the Landing Process of Innovative Products and Continuously Consolidating Core Competitiveness in Pharmaceutical Industry 2022-4-7 Corporate News READ MORE
Grand Pharma Announces 2021 Annual Results, Profit Attributable to Owners of the Company Increase 34.0% to HK$2,402.6 million, Continuing to Deepen the Strategic Plan of Global Technological Innovation, Multiple Products will be Lunched Successively to Provide Long-term Momentum 2022-3-18 Corporate News READ MORE
Grand Pharma Entered into an Equity Investment Agreement with ITM in Germany, Further Consolidate the Group’s Comprehensive Industrial Chain Layout in Research, Production and Commercialization of Radionuclides 2022-2-16 Corporate News READ MORE
Grand Pharma’s Global Innovative Radiopharmaceutical Drugs SIR-Spheres® Y-90 Microsphere Injection Were Approved for Commercialization by NMPA in China, For The Treatment of Colorectal Cancer Liver Metastases 2022-2-9 Corporate News READ MORE
GP (HK) Entered into an Exclusive Product Licensing Agreement with ITM in Germany, Strategically Plans Three Global Innovative RDC Drugs, Significant Milestone in the Field of Radionuclide Drugs 2021-12-27 Corporate News READ MORE
English
